Results of the two incidence screenings in the National Lung Screening Trial.

BACKGROUND The National Lung Screening Trial was conducted to determine whether three annual screenings (rounds T0, T1, and T2) with low-dose helical computed tomography (CT), as compared with chest radiography, could reduce mortality from lung cancer. We present detailed findings from the first two incidence screenings (rounds T1 and T2). METHODS We evaluated the rate of adherence of the participants to the screening protocol, the results of screening and downstream diagnostic tests, features of the lung-cancer cases, and first-line treatments, and we estimated the performance characteristics of both screening methods. RESULTS At the T1 and T2 rounds, positive screening results were observed in 27.9% and 16.8% of participants in the low-dose CT group and in 6.2% and 5.0% of participants in the radiography group, respectively. In the low-dose CT group, the sensitivity was 94.4%, the specificity was 72.6%, the positive predictive value was 2.4%, and the negative predictive value was 99.9% at T1; at T2, the positive predictive value increased to 5.2%. In the radiography group, the sensitivity was 59.6%, the specificity was 94.1%, the positive predictive value was 4.4%, and the negative predictive value was 99.8% at T1; both the sensitivity and the positive predictive value increased at T2. Among lung cancers of known stage, 87 (47.5%) were stage IA and 57 (31.1%) were stage III or IV in the low-dose CT group at T1; in the radiography group, 31 (23.5%) were stage IA and 78 (59.1%) were stage III or IV at T1. These differences in stage distribution between groups persisted at T2. CONCLUSIONS Low-dose CT was more sensitive in detecting early-stage lung cancers, but its measured positive predictive value was lower than that of radiography. As compared with radiography, the two annual incidence screenings with low-dose CT resulted in a decrease in the number of advanced-stage cancers diagnosed and an increase in the number of early-stage lung cancers diagnosed. (Funded by the National Cancer Institute; NLST ClinicalTrials.gov number, NCT00047385.).

[1]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[2]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[3]  D. Aberle,et al.  Results of initial low-dose computed tomographic screening for lung cancer. , 2013, The New England journal of medicine.

[4]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[5]  Christoph Plass,et al.  Lung cancer epigenetics and genetics , 2008, International journal of cancer.

[6]  D. Lynch,et al.  The National Lung Screening Trial: overview and study design. , 2011, Radiology.

[7]  David F Yankelevitz,et al.  Definition of a Positive Test Result in Computed Tomography Screening for Lung Cancer , 2013, Annals of Internal Medicine.

[8]  A. Dirksen,et al.  The Danish Randomized Lung Cancer CT Screening Trial—Overall Design and Results of the Prevalence Round , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Debashis Kushary,et al.  Bootstrap Methods and Their Application , 2000, Technometrics.

[10]  Harry J de Koning,et al.  Management of lung nodules detected by volume CT scanning. , 2009, The New England journal of medicine.

[11]  B. Knight.  The Cause of Death , 1986, Journal of the Royal Society of Medicine.

[12]  J. Crapo,et al.  The Application of Clinical Genetics Dovepress Genetic Evidence Linking Lung Cancer and Copd: a New Perspective , 2022 .

[13]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[14]  D. Aberle,et al.  The National Lung Screening Trial's Endpoint Verification Process: determining the cause of death. , 2011, Contemporary clinical trials.

[15]  Timothy R Church,et al.  Selection criteria for lung-cancer screening. , 2013, The New England journal of medicine.

[16]  Jame Abraham,et al.  Reduced lung cancer mortality with low-dose computed tomographic screening , 2011 .

[17]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[18]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Ayman El-Baz,et al.  Computer-Aided Diagnosis Systems for Lung Cancer: Challenges and Methodologies , 2013, Int. J. Biomed. Imaging.

[20]  S. Lam,et al.  Computed Tomography Screening for Lung Cancer: What Is a Positive Screen? , 2013, Annals of Internal Medicine.

[21]  M. Rinaldi,et al.  Reducing the risk of overdiagnosis in lung cancer: A support from molecular biology , 2011, Journal of cellular physiology.

[22]  J Anthony Seibert,et al.  Description and implementation of a quality control program in an imaging-based clinical trial. , 2006, Academic radiology.

[23]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[24]  Denise R. Aberle,et al.  Baseline Characteristics of Participants in the Randomized National Lung Screening Trial , 2010, Journal of the National Cancer Institute.